NCT05177939View on ClinicalTrials.gov

Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

PHASE3UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

May 31, 2024

Study Completion Date

October 31, 2024

Conditions
Autoimmune Encephalitis
Interventions
DRUG

NPB-01

NPB-01 will be administered for the treatment of autoimmune encephalitis

DRUG

NPB-01-ME

NPB-01-ME will be administered for the treatment of autoimmune encephalitis

Trial Locations (1)

Unknown

RECRUITING

Trial site 1, Ube

Sponsors
All Listed Sponsors
lead

Nihon Pharmaceutical Co., Ltd

INDUSTRY